Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.10+0.26 (+3.80%)
Close on Nov 18, 2026Market cap $27.18MP/E –Yield –
Pelthos Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pelthos Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$42.30M. For fiscal 2025 it was -$22.59M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.59M | – |
| FY2024 | Dec 31, 2024 | -$5.79M | – |
| FY2023 | Dec 31, 2023 | -$981.03K | – |
| FY2022 | Dec 31, 2022 | -$1.57M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$447.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$632.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$670.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$177.69K | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$356.81K | – |
| Q3 FY2023 | Sep 30, 2023 | -$257.24K | – |
| Q2 FY2023 | Jun 30, 2023 | -$193.62K | – |
| Q1 FY2023 | Mar 31, 2023 | -$173.37K | – |
See a number that looks wrong?